Dicot Pharma AB’s Post

"Certain periods in a company’s life stick in the memory more than others. Our second quarter definitely qualifies as one of those." In our interim report, released today, Elin eloquently captures the general sentiment of a period marked by numerous events and significant progress. To read the full interim report in English, click here: https://lnkd.in/d4q5JUzj And in Swedish here: https://lnkd.in/dNdHrNep #q2 #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

The Annual Report 2023 is now available! In addition to the essential financial section, we explore various facets of the past year. This includes an article highlighting our giant leap into clinical studies, along with an engaging interview featuring CTO Mats Silvander who was asked to encapsulate the Dicot culture in just three words. Read the Annual Report in Swedish here (English version will be released shortly): https://lnkd.in/dqsVPkxZ #annualreport2023 #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Don’t miss out! Today we initiate the subscription period for our rights issue. With preferential rights to existing shareholders. However, anyone who wishes to participate can apply interest in subscribing units. Learn more here (in English): https://lnkd.in/d6ibqxRB And here (in Swedish): https://lnkd.in/drhRvzcH #dicotpharmarightsissue #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner  #erektionssvikt #tidigutlösning

Today we proudly announce fantastic results from the first part of our clinical phase 1 trial, the first study in humans. The SAD shows that LIB-01 has a very good safety profile! The results also conclude that the drug is well absorbed in the body with our oral formulation, which is a strong outcome and somewhat unique in this phase.   In parallel the second part of the phase 1-study, the MAD, is ongoing. These results are expected during quarter two.  Read the press release here: https://lnkd.in/dfUX8av7 #clinicaltrials #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

TraceLink protects the medicine supply against drug shortages, external manufacturing issues, and supply chain disruption, providing critical visibility, process collaboration, and actionable intelligence for life science companies and their network partners. Let’s connect at the AAM Annual Meeting to talk about how TraceLink helped protect over 500,000 patients from drug shortages in 2023. Learn more: https://lnkd.in/etVSQNB #SupplyChainOrchestration #DrugShortages #Pharma #Pharmaceutical #Access!

TraceLink protects the medicine supply against drug shortages, external manufacturing issues, and supply chain disruption, providing critical visibility, process collaboration, and actionable intelligence for life science companies and their network partners. Let’s connect at the AAM Annual Meeting to talk about how TraceLink helped protect over 500,000 patients from drug shortages in 2023. Learn more: https://lnkd.in/etVSQNB #SupplyChainOrchestration #DrugShortages #Pharma #Pharmaceutical #Access!

TraceLink protects the medicine supply against drug shortages, external manufacturing issues, and supply chain disruption, providing critical visibility, process collaboration, and actionable intelligence for life science companies and their network partners. Let’s connect at the AAM Annual Meeting to talk about how TraceLink helped protect over 500,000 patients from drug shortages in 2023. Learn more: https://lnkd.in/etVSQNB #SupplyChainOrchestration #DrugShortages #Pharma #Pharmaceutical #Access!

TraceLink protects the medicine supply against drug shortages, external manufacturing issues, and supply chain disruption, providing critical visibility, process collaboration, and actionable intelligence for life science companies and their network partners. Let’s connect at the AAM Annual Meeting to talk about how TraceLink helped protect over 500,000 patients from drug shortages in 2023. Learn more: https://lnkd.in/etVSQNB #SupplyChainOrchestration #DrugShortages #Pharma #Pharmaceutical #Access!

Stay updated with DICOTnytt! Want a quick browse through on the latest in Dicot? Here’s our bi-monthly newsletter, this time highlighting development progress, a conference hat trick, and better international visibility for our share. Click here (in Swedish): https://lnkd.in/dgHGhSFK #dicotnytt #clinicaltrials #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning

Today, our Board of Directors approved a rights issue of units of approximately SEK 123 million with preferential rights for our valued existing shareholders. The subscription period will be from August 16 to 30.   We are also very pleased that the issue is secured up to approximately SEK 80 million. This ensures we have sufficient funds to commence the planned phase 2a trial.   Read more in this press release: https://lnkd.in/dHa475Rb   To our rights issue page (in Swedish): https://lnkd.in/drhRvzcH #rightsissue #företrädesemission #pharma #pharmaceutical #drugdevelopment #sexualdysfunctions #erectiledysfunction #prematureejaculation #lifescience #kliniskastudier #läkemedelsutveckling #sexuelladysfunktioner #erektionssvikt #tidigutlösning